Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
The Clorox Company director reports new deferred stock units tied to CLX common stock. A Form 4 filing shows acquisitions of derivative securities classified as deferred stock units on several 2025 dates. These units convert into Clorox common stock on a 1-for-1 basis.
The director acquired 227.0333 deferred stock units on 11/06/2025 and additional amounts of 1,637.8577 and 272.7363 deferred stock units on 12/31/2025, all at a price of $0.0000 per unit. Following these transactions, the director directly beneficially owns 21,596.5756 deferred stock units.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent an annual award under the 2005 Stock Incentive Plan, and others reflect electing to receive quarterly director fees in deferred stock units. These units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Company director equity compensation and fee deferral is reported in this insider trading disclosure. The filing shows several awards of deferred stock units, each representing the right to receive an equal number of Clorox common shares.
On 11/06/2025, the director acquired 179.1424 deferred stock units at an exercise price of $0.0000, bringing the balance to 15,533.383 units held directly. On 12/31/2025, the director acquired an additional 1,637.8577 deferred stock units and a further 334.7218 units, increasing direct holdings to about 17,505.9625 deferred stock units.
The disclosure notes that some units were obtained through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, others as the annual deferred stock unit award under the 2005 Stock Incentive Plan, and others received instead of quarterly director cash fees. The units will be settled 100% in Clorox stock upon the director’s retirement or other termination of board service.
The Clorox Company director reports additional deferred stock units related to board compensation and dividend reinvestment. On November 6, 2025, the director acquired 199.1684 deferred stock units, each convertible into one share of Clorox common stock, at a price of $0.0000 per unit, bringing the total beneficially owned to 17,269.8302 units.
On December 31, 2025, the director received an additional 1,637.8577 deferred stock units as an annual award and 520.6784 deferred stock units in lieu of quarterly director fees, increasing total holdings to 19,428.3663 deferred stock units. These units are credited under Clorox’s independent director compensation plans and will be settled in Clorox stock when the director retires or otherwise leaves the board.
The Clorox Company director reported several deferred stock unit transactions. On 11/06/2025, the director acquired 63.1574 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan on a 1-for-1 basis with Clorox common stock. On 12/31/2025, the director received 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, and 272.7363 deferred stock units in lieu of quarterly director fees. All units have an exercise price of $0.0000 and each unit represents one share of Clorox common stock. Following these transactions, the director beneficially owns 7,386.9498 deferred stock units, which will be settled in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. (CLX) disclosed a Form 4 for a director reporting routine deferred stock unit activity during 2025. The filing shows multiple acquisitions of deferred stock units tied to Clorox common stock, including 74.9914 units on 02/14/2025, 82.9936 on 05/09/2025, 97.043 on 08/29/2025, 109.0592 on 11/06/2025, and an annual award of 1,637.8577 units on 12/31/2025, all at a price of $0.0000.
After these transactions, the director beneficially owns 11,094.3468 deferred stock units directly. The units are credited on a 1-for-1 basis and will be settled 100% in Clorox stock in connection with the director’s retirement or other termination of service. Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and the year-end grant was made under the 2005 Stock Incentive Plan.
The Clorox Company director reported routine equity compensation activity in the form of deferred stock units. The filing shows several acquisitions of deferred stock units tied to Clorox common stock during 2025, including transactions dated 02/14/2025, 05/09/2025, 08/29/2025, 11/06/2025, and 12/31/2025. These awards were recorded at an exercise price of $0.0000 per unit.
The director’s beneficial holdings in these derivative securities increased to 15,677.4328 deferred stock units held directly. The explanation notes that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, while an additional annual award was granted under the 2005 Stock Incentive Plan. Each deferred stock unit represents a 1-for-1 right to receive Clorox stock, to be settled in shares upon the director’s retirement or other termination of service from the board.
The Clorox Company director reports routine deferred stock awards. A board member of Clorox (ticker CLX) reported several grants of deferred stock units that each convert 1-for-1 into Clorox common stock. On 11/06/2025, the director acquired 219.3396 deferred stock units, bringing the beneficial holding to 19,018.8638 units. On 12/31/2025, additional awards of 1,219.1572 and 145.2617 deferred stock units increased the total to 20,383.2827 units held directly.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent the annual deferred stock unit award under the 2005 Stock Incentive Plan, and some reflect stock units received instead of a portion of quarterly director fees. All deferred stock units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Co. director deferred stock unit grants and reinvestments
A director of Clorox Co. reported multiple acquisitions of deferred stock units tied to Clorox common stock during 2025. On several dates, including 02/14/2025, 05/09/2025, 08/29/2025, and 11/06/2025, small fractional amounts of deferred stock units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, each at an exercise price of $0.0000 and on a 1-for-1 basis into Clorox stock.
On 12/31/2025, the director received an additional 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, also with a conversion price of $0.0000. Following these transactions, the director beneficially owned a total of 4,471.9997 deferred stock units, which will be settled 100% in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.
On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.
The Clorox Company reported a routine equity grant to a director. On 12/31/2025, the director received an annual award of 1-for-1 Deferred Stock Units under the company’s 2005 Stock Incentive Plan. The transaction, reported on a Form 4 for one reporting person, shows 1,637.8577 Deferred Stock Units credited at a price of $0.0000 per unit.
The Deferred Stock Units are tied to Clorox common stock and will be settled 100% in Clorox shares in connection with the director’s retirement or other termination of board service. The filing characterizes this as an annual award, reflecting ongoing non-cash compensation for board service rather than an open-market purchase or sale.
FAQ
What is the current stock price of Clorox Co Del (CLX)?
What is the market cap of Clorox Co Del (CLX)?
